Treating Neurodegenerative Disorders Linked to TDP-43 Pathology

SLU ID 22-001 | RNA-based approach to decrease TDP-43 pathology

Intellectual Property Status

Seeking

  • Provisional patent application filed

  • Know-how based

  • Licensee

  • Development partner

  • Commercial partner

  • Investment

  • University spin out

Background

TDP-43 protein aggregation and loss of function are hallmarks of Amyotrophic Lateral Sclerosis (ALS), frontotemporal dementia, limbic-predominant age-related encephalopathy, Alzheimer's disease, multisystem proteinopathy, and chronic traumatic encephalopathy. Currently, there are no treatments for neurodegenerative disorders linked to TDP-43 pathology.

Overview

Researchers at Saint Louis University have designed and investigated specific molecules to decrease TDP-43 aggregation and recover protein function.

Benefits

The potential benefits of this technology include:

  • increasing the number of potential treatments for various neurodegenerative disorders linked to TDP-43 pathology.

Applications

Potential applications of this technology include developing treatments for:

  • Amyotrophic Lateral Sclerosis (ALS)

  • frontotemporal dementia

  • limbic-predominant age-related encephalopathy

  • Alzheimer's disease

  • multisystem proteinopathy

  • chronic traumatic encephalopathy

Opportunity

Saint Louis University is seeking a partner to further develop and commercialize this technology.